Tryptamine Therapeutics Ltd
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more
Market Cap & Net Worth: Tryptamine Therapeutics Ltd (TYP)
Tryptamine Therapeutics Ltd (AU:TYP) has a market capitalization of $33.88 Million (AU$54.72 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25525 globally and #563 in its home market, demonstrating a 6.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tryptamine Therapeutics Ltd's stock price AU$0.03 by its total outstanding shares 1609510143 (1.61 Billion).
Tryptamine Therapeutics Ltd Market Cap History: 2018 to 2026
Tryptamine Therapeutics Ltd's market capitalization history from 2018 to 2026. Data shows change from $484.84 Million to $33.88 Million (-30.71% CAGR).
Tryptamine Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tryptamine Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.72x
Tryptamine Therapeutics Ltd's market cap is 17.72 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $484.84 Million | $43.92K | -$174.60K | 11039.42x | N/A |
| 2020 | $502.48 Million | $2.62 Million | -$5.22 Million | 192.12x | N/A |
| 2021 | $458.43 Million | $4.19 Million | -$8.46 Million | 109.36x | N/A |
| 2022 | $52.92 Million | $99.73K | -$10.17 Million | 530.62x | N/A |
| 2023 | $10.96 Million | $618.57K | -$7.13 Million | 17.72x | N/A |
Competitor Companies of TYP by Market Capitalization
Companies near Tryptamine Therapeutics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Tryptamine Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Tryptamine Therapeutics Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Tryptamine Therapeutics Ltd's market cap moved from $484.84 Million to $ 33.88 Million, with a yearly change of -30.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$33.88 Million | +3.03% |
| 2025 | AU$32.89 Million | -13.16% |
| 2024 | AU$37.87 Million | +245.45% |
| 2023 | AU$10.96 Million | -79.28% |
| 2022 | AU$52.92 Million | -88.46% |
| 2021 | AU$458.43 Million | -8.77% |
| 2020 | AU$502.48 Million | +119.22% |
| 2019 | AU$229.22 Million | -52.72% |
| 2018 | AU$484.84 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Tryptamine Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $33.88 Million USD |
| MoneyControl | $33.88 Million USD |
| MarketWatch | $33.88 Million USD |
| marketcap.company | $33.88 Million USD |
| Reuters | $33.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.